CD4 and neoplasm: After anti‐CTLA‐4 therapy for prostate tumors, PD‐L1 and V‐domain Ig suppressor of T‐cell activation expression significantly increases on CD4+ T cells, CD8+ T cells and CD68+ macrophages, and PD‐L1 expression increases on tumor cells [301].